Saniona AB has selected its proprietary GABA-A α5 negative allosteric modulator lead compound, SAN-2465, as a clinical candidate for major depressive disorder following encouraging results in a rodent ...
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results